Most Read Articles
Yesterday
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
30 Jun 2020
Patients with psoriatic arthritis (PsA) often suffer from liver abnormalities, which are associated with higher body mass index (BMI), daily consumption of alcohol, more severe disease, and some therapies, according to a recent study.
Christina Lau, 5 days ago

Pembrolizumab in combination with chemotherapy significantly improves progression-free survival (PFS) vs chemotherapy alone in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), results of the KEYNOTE-355 study have shown.

Corticosteroids use during anti-PD1 treatment tied to poor survival

08 Jun 2020

Use of high-dose steroids for long durations during antiprogrammed cell death protein 1 (anti-PD1) treatment appears to result in poorer survival outcomes, suggests a study.

“The advent of anti-PD1 therapy for cancer treatment has led to improvements in response rates and overall survival,” the investigators said. “However, anti-PD1 therapy has the potential to cause immune-related adverse events (irAEs), which can be treated with corticosteroids if severe.”

This retrospective, single-centre study sought to determine if the use of concomitant steroids influences the efficacy of anti-PD1 therapy. Fifty-five adult patients who received at least four cycles of nivolumab or pembrolizumab for the treatment of melanoma, nonsmall cell lung cancer (NSCLC), or renal cell carcinoma from November 2014 to February 2016 were included.

Participants treated with steroids (prednisone equivalent >10 mg) during anti-PD1 therapy were divided into two cohorts according to the duration of steroid administration of ≤2 weeks or >2 weeks. The investigators then assessed time to disease progression, overall response, and overall survival.

Of the patients, 27 (13 melanoma, 11 NSCLC, and three renal cell carcinoma) required steroids during anti-PD1 therapy. The median time to disease progression in these individuals was 5.6 months for melanoma, 5.8 for NSCLC, and 2.0 for renal cell carcinoma.

The overall response rates were 23 percent (3/13), 54 percent (6/11), and 33 percent (1/3) for melanoma, NSCLS, and renal cell carcinoma, respectively. Moreover, the median overall survival was 11.9 months for melanoma, 9.9 for NSCLS, and not reached for renal cell carcinoma.

Of the patients who had received steroids, 13 died, and 11 of these had been treated with prednisone >10 mg/day for >2 weeks.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Yesterday
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
30 Jun 2020
Patients with psoriatic arthritis (PsA) often suffer from liver abnormalities, which are associated with higher body mass index (BMI), daily consumption of alcohol, more severe disease, and some therapies, according to a recent study.
Christina Lau, 5 days ago

Pembrolizumab in combination with chemotherapy significantly improves progression-free survival (PFS) vs chemotherapy alone in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), results of the KEYNOTE-355 study have shown.